Ambrisentan plus Spironolactone + Ambrisentan plus Placebo
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pulmonary Arterial Hypertension
Conditions
Pulmonary Arterial Hypertension
Trial Timeline
Sep 1, 2015 → Feb 1, 2018
NCT ID
NCT02253394About Ambrisentan plus Spironolactone + Ambrisentan plus Placebo
Ambrisentan plus Spironolactone + Ambrisentan plus Placebo is a approved stage product being developed by Gilead Sciences for Pulmonary Arterial Hypertension. The current trial status is terminated. This product is registered under clinical trial identifier NCT02253394. Target conditions include Pulmonary Arterial Hypertension.
What happened to similar drugs?
20 of 20 similar drugs in Pulmonary Arterial Hypertension were approved
Approved (20) Terminated (1) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02253394 | Approved | Terminated |
Competing Products
20 competing products in Pulmonary Arterial Hypertension